prikaz prve stranice dokumenta Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study
  Download
PDF 471.61 KB
Scientific paper - Original scientific paper
Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study
Antibiotics, 11 (2022), 2; 176. https://doi.org/10.3390/antibiotics11020176
Papst, Lea; Luzzati, Roberto; Carević, Biljana; Tascini, Carlo; Gorišek Miksić, Nina; Vlahović Palčevski, Vera; Djordjevic, Zorana M.; Simonetti, Omar; Sozio, Emanuela; Lukić, Milica; Stevanović, Goran; Petek, Davor; Beović, Bojana

Linked objects
COVID-19 (zbirka 2.) | Virtual collection

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Papst, L., Luzzati, R., Carević, B., Tascini, C., Gorišek Miksić, N., Vlahović Palčevski, V. ... Beović, B. (2022). Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study. Antibiotics, 11. (2). doi: 10.3390/antibiotics11020176

Papst, Lea, et al. "Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study." Antibiotics, vol. 11, no. 2, 2022. https://doi.org/10.3390/antibiotics11020176

Papst, Lea, Roberto Luzzati, Biljana Carević, Carlo Tascini, Nina Gorišek Miksić, Vera Vlahović Palčevski, Zorana M. Djordjevic, et al. "Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study." Antibiotics 11, no. 2 (2022). https://doi.org/10.3390/antibiotics11020176

Papst, L., et al. (2022) 'Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study', Antibiotics, 11(2). doi: 10.3390/antibiotics11020176

Papst L, Luzzati R, Carević B, Tascini C, Gorišek Miksić N, Vlahović Palčevski V, and sur.. Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study. Antibiotics [Internet]. 2022 January 28 [cited 2024 December 26];11(2). doi: 10.3390/antibiotics11020176

L. Papst, et al., "Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study", Antibiotics, vol. 11, no. 2, January 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:087238. [Accessed: 26 December 2024]

Metadata
Title (english)Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study
AuthorLea Papst
AuthorRoberto Luzzati
AuthorBiljana Carević
AuthorCarlo Tascini
AuthorNina Gorišek Miksić
AuthorVera Vlahović Palčevski
AuthorZorana M. Djordjevic
AuthorOmar Simonetti
AuthorEmanuela Sozio
AuthorMilica Lukić
AuthorGoran Stevanović
AuthorDavor Petek
AuthorBojana Beović
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Clinical Pharmacology and Toxicology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
Studies suggest that the incidence of coinfections in patients with the coronavirus disease 2019 (COVID-19) is low, but a large number of patients receive antimicrobials during hospitalisation. This may fuel a rise in antimicrobial resistance (AMR). We conducted a multicentre point-prevalence survey in seven tertiary university hospitals (in medical wards and intensive care units) in Croatia, Italy, Serbia and Slovenia. Of 988 COVID-19 patients, 521 were receiving antibiotics and/or antifungals (52.7%; range across hospitals: 32.9–85.6%) on the day of the study. Differences between hospitals were statistically significant (χ2 (6, N = 988) = 192.57, p < 0.001). The majority of patients received antibiotics and/or antifungals within 48 h of admission (323/521, 62%; range across hospitals: 17.4–100%), their most common use was empirical (79.4% of prescriptions), and pneumonia was the main indication for starting the treatment (three-quarters of prescriptions). The majority of antibiotics prescribed (69.9%) belonged to the “Watch” group of the World Health Organization AWaRe classification. The pattern of antimicrobial use differed across hospitals. The data show that early empiric use of broad-spectrum antibiotics is common in COVID-19 patients, and that the pattern of antimicrobial use varies across hospitals. Judicious use of antimicrobials is warranted to prevent an increase in AMR.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleAntibiotics
Numberingvol. 11, no. 2, 176
e-ISSN2079-6382
DOIhttps://doi.org/10.3390/antibiotics11020176
URN:NBNurn:nbn:hr:184:087238
Publication2022-01-28
Document URLhttps://www.mdpi.com/2079-6382/11/2/176
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-09-22 12:11:38